GlassScriptPhysician profile
Michael Adel Daniel Rofael
NPI 1992171805
$10,682.45
in general payments reported to CMS, 2019-2025
28 companies · $1,816 in 2025
The $1,816 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,528 · 2020: $1,835 · 2021: $49.51 · 2022: $532 · 2023: $1,894 · 2024: $1,029 · 2025: $1,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,376 · Travel and Lodging: $2,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,376.19 |
| Travel and Lodging | $2,362.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $3,993.04 | 2019-2020 | |
| Abbott Laboratories | $3,275.22 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Aveir |
| Boston Scientific Corporation | $1,507.15 | 2019-2025 | General - Vascular Access, Avvigo Guidance System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $210.53 | 2020-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.32 | 2024-2025 | Jardiance |
| Pfizer INC. | $167.51 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $166.77 | 2022-2025 | Onpattro, Amvuttra |
| Astrazeneca Pharmaceuticals LP | $148.11 | 2023-2025 | Farxiga, Wainua, Lokelma |
| Novartis Pharmaceuticals Corporation | $129.37 | 2024-2025 | |
| Novo Nordisk INC | $128.51 | 2024-2025 | Wegovy |
| Teleflex LLC | $113.26 | 2022 | |
| Abiomed | $103.78 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.98 | 2024-2025 | |
| Scpharmaceuticals INC. | $67.45 | 2024-2025 | |
| Zoll Circulation INC | $48.27 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $45.91 | 2025 | Attruby |
| Merck Sharp & Dohme LLC | $45.60 | 2024-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $39.08 | 2024-2025 | Camzyos |
| Amgen INC. | $32.36 | 2021-2023 | Repatha |
| Philips North America LLC | $30.48 | 2024 | (Ck4) Mcot |
| Biosense Webster, INC. | $25.51 | 2019 | |
| Penumbra, INC. | $23.58 | 2024 | Indigo System |
| Edwards Lifesciences Corporation | $22.87 | 2025 | Sapien 3 Ultra Resilia |
| Chiesi USA, INC. | $22.68 | 2025 | Kengreal |
| Daxor Corporation | $22.25 | 2024 | Bva-100 |
| Actelion Pharmaceuticals US, INC. | $20.56 | 2024 | Opsumit, Uptravi |
| Cardiovascular Systems INC. | $12.84 | 2022 | |
| Amryt Pharma Holdings LTD | $12.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rofael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.